Metabolism leaves its mark on the powerhouse: recent progress in post-translational modifications of lysine in mitochondria

Kyriakos N. Papanicolaou, Brian O’Rourke and D. Brian Foster*

Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Edited by:
Amadou K. S. Camara, Medical College of Wisconsin, USA

Reviewed by:
Paul S. Brookes, University of Rochester, USA
Christopher Baines, University of Missouri-Columbia, USA
Martin Bienengraeber, Medical College of Wisconsin, USA

*Correspondence:
D. Brian Foster, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Ross Research Building, Room 847, 720 Rutland Avenue, Baltimore, MD 21205, USA
 e-mail: dbrianfoster@jhu.edu

INTRODUCTION

Though mitochondria are the primary site for ATP production, they have also emerged as hubs of control within a cell. What fuel source to use, whether to divide or fuse, to live or die—these are only a few of the decisions made at the level of mitochondria that require the integration of signals about nutrient availability, redox status, and overall health of the cell. Defining these signals is key to understanding mitochondrial function and designing therapies to minimize mitochondrial dysfunction during disease. Evidence indicates that mitochondrial processes are subject to modulation by a number of post-translational modifications (PTM), including phosphorylation of serines, threonines, and tyrosines, as well as through the redox-induced modification of reactive cysteines to yield glutathionylated and S-nitrosylated proteins (reviewed in Foster et al., 2009; O’Rourke et al., 2011; Mailloux et al., 2014).

In this review, we consider the PTM of lysine residues, concentrating primarily on those found in the mitochondrion. What has become clear over the last few years is that there is an emerging class of lysine modifications that stem from the reaction of proteins with thioester-CoenzymeA (CoA) byproducts of metabolism. We begin by surveying the field of mitochondrial lysine acetylation, before introducing more recently discovered PTMs, including succinylation, malonylation, and glutarylation. In each case, we address some key questions. What protein substrates are modified and how is function affected? Are these PTMs modulated by enzymes and, if so, what factors govern their activity? How dynamic are these processes and what is their stoichiometry? The answers to these questions will help shape our perception of these new PTMs, i.e., do they constitute a novel form of signaling, or is their accumulation simply a form of “metabolic stress” to be minimized? Finally, where applicable, we spotlight recent work in cardiac mitochondria, and examine the role of these PTMs in models of heart disease.

LYSINE ACETYLATION

Biological acetylation of histones was first reported by Allfrey et al. (1964), though initial measurements primarily captured N-terminal acetylation, i.e., the reaction with the α-amino group of the mature histone’s first amino acid. It was not until 1968 that investigators realized there was a second, more labile, population of acetylated residues in histones, labeled at the ε-amino group of internal lysine residues (Gershey et al., 1968). The transfer of an acetyl group from acetyl-CoA to the ε-amino group neutralizes lysine’s positive charge. In the nucleus, this is a critical step in gene regulation, and is acutely regulated by the specific action of enzymes: the histone acetyl transferases (HATs) and deacetylases (HDACs). In the mid-2000’s, advances in mass spectrometry coupled with the development of acetylation specific antibodies greatly expanded the catalog of lysine acetylated proteins beyond the nucleus, and mitochondrial proteins figure prominently. Lysine acetylomes have been studied extensively in the nucleus, where they play pivotal roles in gene regulation and constitute one of the pillars of epigenetics. In the cytoplasm, they are critical to proteostasis. However, in the last decade we have also witnessed the emergence of mitochondria as a prime locus for post-translational modification (PTM) of lysine thanks, in large measure, to evolving proteomic techniques. Here, we review recent work on evolving set of PTM that arise from the direct reaction of lysine residues with energized metabolic thioester-coenzyme A intermediates, including acetylation, succinylation, malonylation, and glutarylation. We highlight the evolutionary conservation, kinetics, stoichiometry, and cross-talk between members of this emerging family of PTMs. We examine the impact on target protein function and regulation by mitochondrial sirtuins. Finally, we spotlight work in the heart and cardiac mitochondria, and consider the roles acetylation and other newly-found modifications may play in heart disease.

Keywords: acetylation, succinylation, malonylation, glutarylation, heart, sirtuin, Sirt3, Sirt5
PROTEIN LYSINE ACETYLATION IN PROKARYOTES

In prokaryotes, acetylation has emerged as a central regulatory mechanism that coordinates metabolism in response to changes in nutrient status (Wang et al., 2010). In *S. enterica*, 191 proteins are reported to be lysine-acetylated and in *E. coli* this number currently reaches 349 (Wang et al., 2010; Zhang et al., 2013). Metabolic enzymes (e.g., aldolase, Pdh, and Mdh, to name a few) are common substrates for acetylation and ontologic classification shows that acetylation on metabolic regulators is more frequent than that observed, for example, on ribosomal proteins. The prokaryotic enzymes, Pat and CobB, regulate bacterial protein lysine acetylation and deacetylation respectively (Starai et al., 2002; Starai and Escalante-Semerena, 2004; Wang et al., 2010). The balance between acetylation/deacetylation is influenced by several conditions, including switching carbon sources (e.g., from glucose to citrate), growth phase, and availability of acetylphosphate (AcP) (Yu et al., 2008; Zhang et al., 2009; Wang et al., 2010; Weinert et al., 2013a). Consensus sites that may serve as hotspots for lysine acetylation/deacetylation have been examined and, although no distinct patterns emerge, having tyrosine or histidine at site +1 frequently correlates with acetylation (Zhang et al., 2009), though not in all bacterial species examined (Kim et al., 2013). Estimates of stoichiometry in *E. coli*, indicate that, for the bulk of acetylated lysines, occupancy is below 1% (Weinert et al., 2013a). This is consistent with more recent calculations, showing that the stoichiometry for 82% of acetylated sites was equal or below 10% and only a small fraction of sites (4%) exhibited stoichiometries larger than 20% (Baeza et al., 2014). High acetylation stoichiometries were found in proteins participating in metabolic pathways including the pentose phosphate pathway, glycolysis and the tricarboxylic acid (TCA) cycle (Baeza et al., 2014).

The observation that acetylation occupancy is low for the majority of sites prompts the question as to whether it serves as a regulatory PTM or is simply a non-specific epiphenomenon of metabolism. Ultimately, the answer is likely a bit of both, though it would be prudent not to summarily dismiss a site’s regulatory potential on the basis of low stoichiometry alone. Though most would agree that high site stoichiometry is a promising sign of its potential for protein regulation, it is no guarantee. Conversely, low PTM stoichiometry can have profound regulatory consequences if the target performs a key step in feed-forward processes such as enzymatic cascades or co-operative systems.

Regardless of stoichiometry, there are clearly examples of functional regulation by acetylation/deacetylation in prokaryotes. In *S. enterica* acetylation of GapA (prokaryotic homolog of Gapdh) stimulates glycolysis, while deacetylation reverses the equilibrium toward gluconeogenesis (Wang et al., 2010). This model illustrates one example where acetylation promotes the enzymatic activity of its substrate and feeds forward for the production of more acetyl-CoA through glycolysis. An example of feedback inhibition in *S. enterica* is the regulation of Acs (acytetyl-CoA synthetase) by Pat and CobB. When acetyl-CoA is in excess, Acs is acetylated and deactivated by Pat and when glycolytic substrates become limited, CobB deacetylates Acs and activates the enzyme to synthesize acetyl-CoA from acetate (Thao and Escalante-Semerena, 2011). Another example in *E. coli* is the regulation of RNA polymerase (RNAPu) via acetylation at the C terminal domain (CTD) (Lima et al., 2012). With bacterial acetylomes expanding, we expect that more examples of protein regulation by acetylation will emerge thus improving our understanding of the biological significance of this modification.

PROTEIN LYSINE ACETYLATION IN YEAST AND FLIES

Acetylomes have been reported for model organisms such as *Saccharomyces cerevisiae* (Brewer's yeast) and *Drosophila melanogaster* (fruit fly), while for others, such as *Caenorhabditis elegans* (nematode worm) and *Danio rerio* (zebrafish), large-scale proteomic assessments of lysine acetylation have yet to be described. Current studies have identified 959 or 1059 acetylated proteins in yeast (Henriksen et al., 2012; Weinert et al., 2013b) and 1013 acetylated proteins in the SL2 fruit fly cell line (Weinert et al., 2011). Proteins from every functional class are subject to acetylation (e.g., RNA processing, protein synthesis) while almost every enzyme participating in major metabolic pathways (e.g., glycolysis, gluconeogenesis) is acetylated in yeast (Henriksen et al., 2012). The evolutionary conservation of acetylated lysines is higher than non-acetylated lysines (Weinert et al., 2011; Henriksen et al., 2012) and sites of lysine acetylation are more tightly conserved than sites of phosphorylation (Weinert et al., 2011). Nevertheless, the stoichiometry of phosphorylation in yeast is significantly higher than acetylation, where the majority of acetylated sites have stoichiometries lower than 1% (Weinert et al., 2013b). The few exceptions with high acetylation stoichiometries are proteins already known to undergo acetylation by specific acetyl-transferases (largely related to acetylation in the nucleus). For other proteins, acetylation may occur as a low-frequency, non-enzymatic reaction driven by the concentration of acetyl-CoA (Weinert et al., 2013b). As discussed below, non-enzymatic modification is one of the proposed mechanisms underlying the acetylation of proteins in mitochondria (Newman et al., 2012; Wagner and Payne, 2013; Weinert et al., 2013b).

CHEMICAL AND ENZYMATIC CONTROL OF MITOCHONDRIAL ACETYLATION/DEACETYLATION IN MAMMALS

As in prokaryotes, lysine acetylation in mitochondria is tightly coupled to nutrient availability. The mechanism underlying acetylation, however, is still debated. It has been recently suggested that elevated pH in the mitochondrial matrix is favorable for the acetylation reaction (Wagner and Payne, 2013). Moreover, the mitochondrial matrix is where enzymes of the TCA cycle maintain high concentrations of acetyl-CoA. Together, these conditions would favor non-enzymatic formation of acetyl-lysines (Wagner and Payne, 2013). Additionally, Gcn5L1 is recently identified as a putative mitochondrial acetyltransferase in HepG2 cells (Scott et al., 2012). Gcn5L1, shares sequence similarity with bacterial acetyltransferases, localizes to mitochondria (both in the matrix and the IMS), and promotes mitochondrial protein acetylation in cells and in cell-free systems (Scott et al., 2012). Substrates of Gcn5L1 include electron transport chain (ETC) subunits Ndufa9 and Atp5a. It should be noted however that for full activity, Gcn5L1 requires additional mitochondrial factors and/or partners that are presently unknown. An intriguing observation in the two studies examining non-enzymatic acetylation or
By contrast to acetylation, there is no dearth of information regarding enzyme-driven mitochondrial deacetylation. Mammals host a family of seven genes called sirtuins 1 through 7 (Sirt1-7), due to their sequence homology to yeast silent information regulator 2 (Sir2p) (Haigis and Guarente, 2006). Three of the sirtuins (Sirt3, Sirt4 and Sirt5) are found in mitochondria (Onyango et al., 2002; Schwer et al., 2002; Michishita et al., 2005; Shi et al., 2005). The sirtuins use NAD$^+$ co-substrate, which makes them particularly sensitive to fluctuations in metabolism. Notwithstanding their homology to yeast Sir2p, not all of the mitochondrial isoforms are equally effective as NAD-dependent deacetylases. Of the three mitochondrial sirtuins, Sirt3 appears to have the broadest deacetylation activity in vivo and will be discussed in subsequent sections (Lombard et al., 2007). Sirt4 is more widely recognized for its ADP-riboseyl-transferase activity (Haigis et al., 2006; Ahuja et al., 2007), although some suggest this may not be its major enzymatic role (Du et al., 2009). Sirt4 does exhibit some deacetylation activity in vitro (Rauh et al., 2013) and may have a restricted, but important, set of substrates in vivo. Recently, Sirt4 has been implicated in the coordination of fatty acid metabolism (Laurent et al., 2013a,b), modulation of ATP release from mitochondria (Ho et al., 2013) and tumor suppression by inhibiting glutamine metabolism (Cai et al., 2013; Jeong et al., 2013). It is likely that as our view of the PTM landscape in mitochondria expands, additional substrates and/or activities of Sirt4 will be uncovered. This is exemplified by the case of Sirt5, a sirtuin with limited deacetylation activity, whose function has become clearer since the identification of malonylation and succinylation (more later).

**HARNESSING PROTEOMICS TO MAP PATHWAYS TARGETED BY ACETYLATION**

The breadth of lysine acetylation on mitochondrial proteins was appreciated from the early proteome-wide studies that used cells such as HeLa, Jurkat, NIH/3T3, MV4-11 (an AML cell line) and A549 (an epithelial cell line) (Kim et al., 2006; Choudhary et al., 2009) and also mitochondria fractionated from mouse or human liver (Kim et al., 2006; Zhao et al., 2010). These studies are largely responsible for establishing the proteomic methodology used to identify acetylation sites. The workflow entails the enrichment of post-translationally modified peptides, first by precipitation of proteins (extracted from mitochondria, cells, or whole tissues), digestion with trypsin (and sometimes Lys-C endopeptidase from *Lysobacter enzymogenes*) and immunopurification of acetyl-lysine-bearing peptides using specific antibodies. Peptide capture is followed by chromatographic separation using high performance liquid chromatography and tandem mass spectrometry (MS/MS). The outcomes of such studies include the reporting of 133 acetylated proteins in mouse liver mitochondria (MLM) in 2006, 1395 acetylated proteins in Jurkat cells in 2009 and 1047 acetylated proteins in human liver in 2010 (Kim et al., 2006; Choudhary et al., 2009; Zhao et al., 2010). These methods have now been broadly applied and have proven integral to elucidating which biochemical pathways are subject to modulation by a variety of stimuli.
| Metabolic pathway | Enzyme | Extended enzyme name | K-Ac site verified with functional assay | References | K-Ac site candidate for deacetylation by Sirt3 | References |
|------------------|--------|----------------------|------------------------------------------|------------|---------------------------------------------|------------|
| Glycolysis       | ALDO   | Aldolase              | K147 (r) ↓                               | Lundby et al., 2012 |                                            |            |
|                  | GPD1   | Glycerophosphate dehydrogenase 1 | K120 (r) ↓                               | Lundby et al., 2012 |                                            |            |
| Gluconeogenesis  | PEPCK1 | Phosphoenolpyruvate carboxy kinase 1 | K70, K71, K594 (h) ↓ | Zhao et al., 2010 |                                            |            |
| Fatty acid oxidation | CPT2  | Carnitine palmitoyl transferase 2 |                                            | K510       |                                            | Rardin et al., 2013a |
|                  | VLCAD  | Very long chain Acyl-CoA dehydrogenase |                                            | K299       |                                            | Hebert et al., 2013 |
|                  | LCAD   | Long chain Acyl-CoA dehydrogenase | K42, K318, K322 ↓ | Hirschey et al., 2010; Bharathi et al., 2013 |                                            | Rardin et al., 2013a |
|                  | ACADSB | Short Branched chain Acyl-CoA dehydrogenase |                                            | K284       |                                            | Hallows et al., 2011 |
|                  | SCHAD  | Short chain L3-hydroxy-Acyl-CoA dehydrogenase |                                            | K202       |                                            | Hallows et al., 2011 |
|                  | EHHADH | Enoyl-CoA Hydratase/Hydroxyacyl-CoA dehydrogenase | K171, K346 (h) ↑ | Zhao et al., 2010 |                                            |            |
|                  | ACA2   | AcetylCoA acyltransferase 2 |                                            | K211       |                                            | Rardin et al., 2013a |
| Tricarboxylic acid (TCA) cycle | CS     | Citrate synthase |                                            | K49, K52   |                                            | Rardin et al., 2013a; Hebert et al., 2013 |
|                  | SDHA   | Succinate dehydrogenase subunit A |                                            | K179       |                                            | Hebert et al., 2013; Rardin et al., 2013; Sol et al., 2012 |
|                  | IDH2   | Isocitrate dehydrogenase 2 | K413 ↓ | Yu et al., 2012 | K360                                      | Rardin et al., 2013a |
|                  | ACO2   | Aconitate 2 |                                            | K144       |                                            | Hebert et al., 2013 |
|                  | MDH2   | Malate dehydrogenase 2 | K239 ↓ | Hebert et al., 2013 |                                            | Rardin et al., 2013a |
| Electron transport chain/ ATP synthase | NDUFB11 | NADh-ubiquinone oxidoreductase subunit 11 |                                            | K43        |                                            | Hebert et al., 2013 |
|                  | NDUFV3 | NADH-ubiquinone oxidoreductase flavoprotein subunit 3 |                                            | K46        |                                            | Hebert et al., 2013 |
|                  | COX4   | Cytochrome C oxidase subunit 4 |                                            | K29, K60   |                                            | Hebert et al., 2013; Sol et al., 2012 |
|                  | ATP50  | ATP synthetase subunit 5O |                                            | K84, K97   |                                            | Hebert et al., 2013; Rardin et al., 2013a |
| Aminoacid catabolism | GDH1   | Glutamate dehydrogenase 1 |                                            | K477, K480 |                                            | Rardin et al., 2013a |
|                  | BCKDHA | Branched chain alpha ketoacid dehydrogenase A |                                            | K199       |                                            | Hebert et al., 2013 |
Table 1 | Continued

| Metabolic pathway | Enzyme | Extended enzyme name | K-Ac site candidate for deacetylation by Sirt3 | References |
|-------------------|--------|----------------------|-----------------------------------------------|------------|
| Ketogenesis       | HMGS2  | HMGCoA synthase 2    | K310, K447, K473                               | Shimazu et al., 2010; Rardin et al., 2013a |
|                   | HMGGL  | HMGCoA lyase          | K324                                          | Rardin et al., 2013a |
|                   | ACAT1  | AcetylCoA acetyl transferase 1 | K260, K265                                   | Still et al., 2013; Hebert et al., 2013; Rardin et al., 2013a |
|                   | AceCS1 | AcetylCoA synthetase 1 | K661                                          | Hallovs et al., 2006 |
|                   | AceCS2 | AcetylCoA synthetase 2 | K642(h), K635                                 | Hallovs et al., 2006; Schwer et al., 2006 |
| Urea cycle        | OTC    | Ornithine transcarbamylase | K88                                          | Hallows et al., 2011; Yu et al., 2009 |
|                   | CPS1   | Carbamoylphosphate synthase 1 | K1356, K1486                                 | Hebert et al., 2013; Rardin et al., 2013a |
|                   | ASL    | Argininosuccinate lyase | K288(h)                                      | Zhao et al., 2010 |

Arrows indicate whether the enzyme is activated (up) or inactivated by acetylation (down). Numbering of acetylation sites refers to mouse unless otherwise noted (h, human; r, rat).

is acetylation of ornithine transcarbamylase (Otc) at K88 (see also Table 1 for more examples). The mechanisms underlying enzyme inhibition seem to vary by protein. In certain cases acetylation at sites within or adjacent to the active site prevents catalytic steps such as substrate binding (Lundby et al., 2012; Bharathi et al., 2013; Hebert et al., 2013; Still et al., 2013). In others, such as Pepck1, acetylation is reported to promote degradation of the enzyme (Zhao et al., 2010; Jiang et al., 2011).

STOICHIOMETRY AND DYNAMICS OF PROTEIN LYSINE ACETYLATION IN MAMMALIAN MODELS

Proteomic studies have certainly revealed many mitochondrial acetyl-proteins, but is the extent or stoichiometry of acetylation sufficient to meaningfully affect their function? Fortunately, MS can provide clues on this front as well. For example, using enzyme immunoprecipitation, coupled with a quantitative proteomic strategy that used isobaric tags for relative and absolute quantification (iTRAQ) and the appropriate peptide standards, Zhao et al. estimated that the acetylation stoichiometry of malate dehydrogenase (Mdh2) and Enoyl-CoA Hydratase/Hydroxyacyl-CoA dehydrogenase (Ehhadh), in HEK293T cells ranges from 7% up to 47% depending on the specific site (Zhao et al., 2010). Moreover, acetylation levels increased substantially in response to treatment with trichostatin A and nicotinamide with profound effects on enzyme activity. It is important to note, that interventions such as knocking out genes or inducing acute and chronic changes in nutrition, can lead to changes in protein expression that can confound acetylation site quantification. In these cases, it is important to show that the abundance of the protein of interest does not vary significantly between groups (for example the abundance of Otc, Mdh2, Lcad, Sdha, and Hmgcs is similar between wild-type and Sirt3−/− samples; Rardin et al., 2013a).

Another common approach is to normalize the number of spectra obtained for an acetylated site after immunoenrichment to the total number of spectra obtained for that site in non-enriched samples. This approach was used to quantify changes in acetyl-lysine site occupancy under conditions of CR, fasting and refeeding or chronic overnutrition (Hebert et al., 2013; Still et al., 2013). Using normalization, it has also been estimated that the acetyl-lysine occupancy at K147 in aldolase reaches approximately 30% in the liver (Lundby et al., 2012).

A key corollary is: how long does it take to achieve appreciable changes in acetylation levels? Are the rates of acetylation and deacetylation comparable to those of phosphorylation and dephosphorylation? It has been suggested that factors influencing these dynamics may include intrinsic characteristics of the lysine residue being modified (i.e., position in the tertiary structure, making it more or less accessible for acetylation/deacetylation), or extrinsic factors such as the quantity and activity of deacetylases, or the availability of acetyl-CoA and matrix pH (Wagner and Payne, 2013; Pougovkina et al., 2014a). A survey of the literature reveals that in cell culture, widespread changes in acetylation are reported after 24 h of exposure to deacetylase inhibitors (Choudhary et al., 2009). Similarly, robust acetylation of Otc (see also Table 1) in cell culture is reported after 16 h of exposure to deacetylase inhibitor nicotinamide (Hallows et al., 2011).
mitochondria, changes in acetylation are detected as early as 2 h of acute re-feeding (Still et al., 2013). Fasting for 12 or 24 h also alters the acetylation pattern in MLM (Kim et al., 2006; Hirschey et al., 2010). Likewise acetylation is modulated by modest but long-term chronic changes in feeding. Chronic protocols such as 2 months of CR, 2.5 months of overnutrition or 3 months of high-fat feeding all yield changes in the acetylation patterns in liver mitochondrial proteins (Hirschey et al., 2011; Hebert et al., 2013; Still et al., 2013).

The deacetylase activity and protein levels of Sirt3 are regulated by nutrient availability. During a 16-h fast, Sirt3-dependent deacetylation occurs (Still et al., 2013), yet no changes in protein abundance are detected, suggesting that short-term fasting elicits Sirt3’s enzymatic activity, likely through transient increase of NAD⁺ availability. However, after 24 h of fasting, Sirt3 protein levels significantly increase, through mechanisms requiring the transcriptional activator Pgc-1α (Hirschey et al., 2010). Furthermore, elevated protein levels of Sirt3 in the liver are also found after 2 or 3 months of CR (Hallows et al., 2011; Hebert et al., 2013). On the other hand, Sirt3 protein levels decline in liver mitochondria during the second or third month of high fat feeding (Hirschey et al., 2011). Thus, Sirt3 can respond to both acute and chronic changes in nutrition and its activation or inhibition can greatly influence the acetylation dynamics in mitochondria.

**THE ROLE OF Sirt3 IN THE HEART AND CARDIAC MYOCYTES. CANDIDATE TARGETS FOR DEACETYLATION**

Sirt3-deficient mice have been developed by several groups who, collectively have observed elevated acetylation on mitochondrial proteins in tissues lacking the gene (Lombard et al., 2007; Ahn et al., 2008; Yang et al., 2010; Fernandez-Marcos et al., 2012). Sirt3⁻/⁻ mice have baseline cardiac hypertrophy evident at 4 or 13 months of age (Sundaesran et al., 2009; Hafner et al., 2010), although data from others show no increase in the cardiac mass of Sirt3⁻/⁻ mice at 5 months of age (Someya et al., 2010). Sirt3 is induced in the heart by exercise or pathologic stimuli and is shown to protect against maladaptive cardiac remodeling and improve survival following pressure overload (Sundaesran et al., 2009; Hafner et al., 2010). It would be reasonable to presume that protection stems from deacetylation of mitochondrial substrates, yet initial evidence in cardiac cells has highlighted putative roles of Sirt3 outside mitochondria. Specifically, in neonatal rat ventricular myocytes (NRVMs), Sirt3 deacetylates nuclear protein Ku70, prevents mitochondrial translocation of the proapoptotic protein Bax, and enhances tolerance against H₂O₂ (Sundaesran et al., 2008). Moreover, Sirt3 deacetylates transcription factor Foxo3a, which increases the expression of manganese-dependent superoxide dismutase (MnSOD, Sod2) that, in turn, diminishes the accumulation of superoxide in mitochondria (Sundaesran et al., 2009). Data notwithstanding, it is still debatable whether Sirt3 is a bona fide regulator of Ku70 and Foxo3a, or whether enforced expression of Sirt3 accounts for the observed extra-mitochondrial activity (Bao et al., 2010). Furthermore, a quick survey in the acetylome database (http://cpr1.sund.ku.dk/cgi-bin/PTM.pl) failed to retrieve any acetylated peptides for Ku70 or Foxo3a in the heart, suggesting that the frequency of this modification might be below the detection limits of the MS/MS approach.

Acetylation of Sod2 is of considerable interest, since the enzyme is a critical component of mitochondrial antioxidant defenses and Sod2 deficiency exacerbates cardiac injury in vivo (Lebovitz et al., 1996). Although Sod2 acetylation in the heart has yet to be characterized fully, there is consensus among studies in liver, mouse embryo fibroblasts (MEFs), and HEK cells demonstrating that Sod2 activity is regulated via reversible acetylation and is controlled by Sirt3 (Qiu et al., 2010; Tao et al., 2010; Chen et al., 2011). For example, fasting for 36 h decreases the levels of acetylated Sod2 in the liver without reducing total protein levels and that regulation requires the presence of Sirt3 (Tao et al., 2010). Similarly, CR for 6 months (30% reduction in caloric intake) reduces the acetylation of Sod2 in the liver in a Sirt3-dependent fashion (Qiu et al., 2010). Moreover, Sirt3 is demonstrated to interact with and deacetylate Sod2 in MEFs and HEK293 cells, and in the absence of Sirt3, Sod2 exhibits increased acetylation and inhibited enzymatic activity in vitro (Qiu et al., 2010; Tao et al., 2010; Chen et al., 2011). Interestingly, each of these studies identified different lysine residues as the pivotal sites for regulation of Sod2 via reversible acetylation, including K53, K68 K89 and K122 (see also Table 2). Activation of Sod2 in the liver increases the ratio of [GSH:GSSG] (an index of antioxidant capacity) while decreasing indices of oxidative stress including hydroxynonenal, protein carbonylation and mitochondrial superoxide production (Qiu et al., 2010; Tao et al., 2010).

**PROTEIN ACETYLATION IN THE HEART AND CARDIAC MITOCHONDRIA**

We now shift our attention to examine the roles of lysine acetylation in cardiac mitochondria and in systems that may be extrapolated to the cardiac domain. As in other organisms and organs, models ranging from SIRT ablation to CR, from cell biology to proteomics are providing insights that may one day be harnessed for therapeutic benefit.
Table 2 | Mitochondrial protein acetylation, regulatory sites and significance in cardiac physiology and pathophysiology.

| Mitochondrial process | Protein/enzyme | Regulatory K-Ac site(s) | Conditions affecting acetylation | Experimental system | References | K-Ac sites in heart mitochondria acetylomes |
|-----------------------|----------------|------------------------|----------------------------------|---------------------|------------|-------------------------------------------|
|                       |                |                        |                                  |                     |            | Rat (Lundby et al., 2012) | Mouse (Nguyen et al., 2013) | Guinea pig (Foster et al., 2013) |
| Substrate metabolism   | Acaa2          |                        |                                  |                     |            | K25, K137, K270                 | K25, K137, K270                 | K25, K270                 |
|                       | Lcad           | HF ↑                   | Heart                            | Grillon et al., 2012| K91, K254, K279 | K91, K254, K279 | K91, K254, K279 | K91, K254, K279 |
|                       | Hadha          | CypD deficiency ↑      | Heart                            | Nguyen et al., 2013| K436, K505, K728 | K505, K728 | K505, K728 | K505, K728 |
|                       | Hadhb          | IPC ↑, CypD deficiency ↑| Heart                            | Nadtochiy et al., 2011| K73, K349    | K73, K202 | K73, K202, K349 |
| TCA cycle /ETC /ATP synthesis | Mdh2          | HF ↑                   | Heart                            | Grillon et al., 2012| K105, K165, K328 | K105, K165, K328 | K165, K328 |
|                       | Sdha           | CR ↑, Ndufs4 deficiency ↑| Heart                            | Shirmura et al., 2011| K496, K550, K633 | K498, K550, K633 | K498, K550, K633 |
|                       | Aco2           | CypD deficiency ↑      | Heart                            | Nguyen et al., 2013| K50, K144, K517 | K50, K144, K517 | K50, K517 |
|                       | Ndufa9         | Sirt3 deficiency ↑, Ndufs4 deficiency ↑| Liver, MEFs | Ahn et al., 2008 | K189 | K189 |
|                       | Ndufs1         | CR ↓                   | Heart                            | Shirmura et al., 2011| K450, K499 | K450, K467 | K450, K467 |
|                       | Ndufv1         | IPC ↓, HF ↑            | Heart                            | Nadtochiy et al., 2011| K81, K104, K401 | K81, K104, K401 | K104 |
|                       | Uqcr1          | HF ↑                   | Heart                            | Grillon et al., 2012| K85, K111, K138 | K85, K111, K138 | K85, K111, K138 |
|                       | Uqcrfs1        | CR ↓                   | Heart                            | Shirmura et al., 2011| K46, K168, K172 | K163, K168 | K46 |
|                       | Atp5a1         | CR ↑                   | Heart                            | Shirmura et al., 2011| K427, K531, K539 | K427, K531, K539 | K427, K531, K539 |
|                       | Atp5b          | HF ↑                   | Heart                            | Grillon et al., 2012| K133, K159, K259 | K133, K259 | K133, K259 |
|                       | Ckmt2          | IPC ↓, HF ↑            | Heart                            | Nadtochiy et al., 2011| K276, K292, K355 | K276 | K276 |
| Redox balance         | Sod2           | K122, K53, K89, K68    | Fasting, Sirt3 deficiency ↑, Nutrient starvation ↓| Liver, MEFs, HEK293 | Tao et al., 2010 | K68, K114, K122 | K68, K114 | K68, K122, K130 |
|                       | Idh2           | CR ↓, IPC ↓            | Liver, Brain, Heart              | Someya et al., 2010 | K155, K180, K199 | K155, K180, K413 | K155, K180, K199 |
|                       | Prdx5          |                        | Heart, HEK293                    | Shulga et al., 2010 | K66, K166, K174 | K66, K174 | K66, K174 |
| Permeability transition | CypD           | K166, K166             | Switch from Glc. to Gal., Sirt3 expression ↓| Heart, HEK293 | Shulga et al., 2010 | K66, K166, K174 | K66, K174 |

(Continued)
### Table 2 | Continued

| Mitochondrial process       | Protein/ enzyme | Regulatory K-Ac site(s) | Experimental system | Conditions affecting acetylation | Conditions affecting deacetylation | K-Ac sites in heart mitochondria acetylomes | References |
|-----------------------------|-----------------|------------------------|---------------------|----------------------------------|-----------------------------------|------------------------------------------|------------|
| Membrane fusion             | Opa1            | K326, K351             | Heart, MEFs         | Sirt3 deficiency ↑ cardiac stress | ↑ heart failure, Arrows indicate whether acetylation is increased (↑) or decreased (↓) by the different experimental conditions. K-Ac sites are reported according to mouse numbering; due to space limitations not all acetylated sites are shown; a blank cell indicates that no data are currently available. | Not found | Samant et al., 2013 |
| Translation                 | Mrpl10          | K124, K162, K196       | Liver, HEK293       | Sirt3 expression ↓                | ↓                | Not found | Not found |

Sod2 deacetylation curtails apoptosis in the liver and ameliorates cell death induced by paraquat (an inducer of oxidative stress). In MEFs, the expression of Sod2 deacetylation-mimetic mutants (i.e., K-to-R) abrogates mitochondrial superoxide production (Qiu et al., 2010; Tao et al., 2010). Thus, the activity of Sod2 depends on its acetylation state and it remains to be determined whether a similar mechanism is operable in the heart. Along these lines, it has been very recently reported that partial deficiency in Sirt3 is associated with lower Sod2 enzymatic activity in mouse hearts (Porter et al., 2014). These Sirt3 haploinsufficient hearts also demonstrated increased susceptibility to ischemia/reperfusion (I/R) injury (Porter et al., 2014).

### REGULATION OF PROTEIN ACETYLATION DURING CALORIE RESTRICTION IN NEURONS AND IN HEART

Like cardiac myocytes, neurons are post-mitotic cells with increased energy demands and heightened risk for oxidative damage. CR (25% reduction in calorie intake for 10 months) protected against neuronal death and hearing loss by activating antioxidant mechanisms in mice (Someya et al., 2010). A similar approach (40% reduction in calorie intake for 6 months) was also used to test the effects of CR in cardiac I/R injury in rats (Shinmura et al., 2011). In neurons, the protective effects of CR are mediated by increasing protein levels and activity of Sirt3 (Someya et al., 2010). In the heart, CR increases the overall mitochondrial sirtuin activity, although the protein levels of Sirt3 do not change significantly (Shinmura et al., 2011). In neurons, the anti-aging effects of CR implicate the deacetylation and activation of mitochondrial NADP-dependent isocitrate dehydrogenase 2 (Idh2; activation of this enzyme increases [NADPH:NADP+] ratio, which drives thiol-dependent antioxidant defenses). Likewise, CR up-regulates NADPH concentration and [GSH:GSSG] ratios in neuronal and liver mitochondria. Moreover, Idh2 maintains high levels of [NADPH] in HEK cells and protects against cell death induced by oxidants such as peroxide and menadione (Someya et al., 2010). In the case of heart, CR has protective effects in some but not all post-I/R indices of mitochondrial function. For example, oxygen consumption rates and mitochondrial H2O2 levels are largely unchanged by CR, although mitochondrial swelling due to Ca2+–overload is ameliorated (Shinmura et al., 2011). Acetylation of Idh2 was not studied in the CR-treated heart, but acetylation in a number of other proteins changed (see CR, Table 2). Notably, during this regimen, some mitochondrial proteins were deacetylated (Ndufs1, Uqcrfs1, and Sdha) whereas others became hyperacetylated (Atp5a1) (Shinmura et al., 2011). These targets offer starting points for further research into the cardioprotective mechanisms of CR.

### REGULATION OF CARDIAC PROTEIN ACETYLATION IN HEART FAILURE AND ISCHEMIC PRECONDITIONING

Beyond cardiac I/R injury, mitochondrial protein acetylation has also been studied in the context of ischemic preconditioning (IPC), and experimental heart failure (HF). In the case of IPC, acetylation of mitochondrial proteins can be either upregulated or downregulated, a situation somewhat similar to that observed with CR-treated hearts. For example, the acetylation...
of Hadhb increases whereas that of Ndufv1 decreases during IPC (Nadtochiy et al., 2011) (see also IPC, Table 2). In HF however, there appears to be a more pronounced trend toward increased acetylation. In a study where rats developed HF at 7.5 or 18 months of age, it was determined that 41 or 66 cardiac proteins respectively exhibited increased acetylation (Grillon et al., 2012). Examples of acetylated proteins include Ndufv1, Uqcc1, Mdh2, and Ckmt2 (see also Table 2) (Grillon et al., 2012). Increased mitochondrial protein acetylation is also shown in a murine model of diabetic cardiomyopathy (Vadvalkar et al., 2013). Provided that appropriate normalization is performed for changes in protein abundance, it can be suggested that HF progression is accompanied by increased mitochondrial protein acetylation. Notably, Sirt3 protein levels decrease in failing rat hearts or when H9C2 cardiomyocytes are subjected to oxidative stress (Grillon et al., 2012; Chen et al., 2013). Finally, notwithstanding the protein remodeling that might compromise mitochondrial function during HF progression, it has been shown that acute induction of acetylation chemically with acetic anhydride is sufficient to adversely impact mitochondrial function, specifically lowering state III respiration and elevating ROS production (Vadvalkar et al., 2013). Mitochondrial protein deacetylation might also be necessary for successful cardiac IPC, however the bulk of the current data center on important regulators of IPC in the cytosol. This is supported by the finding that a sirtuin inhibitor, splitomycin, negates the post-ischemic recovery of preconditioned hearts (Nadtochiy et al., 2011). Since splitomycin targets Sirt1 and is likely to block deacetylation of cytoplasmic proteins, it remains an open question whether deacetylation of mitochondrial proteins and the relevant sirtuin Sirt3 is required for effective IPC. It would therefore seem that accumulating evidence supports the argument that mitochondrial lysine acetylation in the heart is harmful. Alternatively, it has also been suggested that acetylcarnitine treatment may alleviate age-related mitochondrial dysfunction, in part, via acetylation and activation of mitochondrially-encoded gene expression (Rosca et al., 2009).

**LYSINE ACETYLATION ON CYCLOPHILIN D**

Cyclophilin D (CypD) operates as a mitochondrial chaperone with cis/trans (C/T) isomerase activity but is best known as a modulator of acute necrotic cell death through the mitochondrial permeability transition (MPT). Studies in cancer cell lines and in HEK cells have suggested that acetylated CypD can more readily sensitize MPT (Hafner et al., 2010; Shulga et al., 2010). In HeLa cells growing in glucose, CypD is acetylated and has enhanced C/T isomerase activity whereas in cells growing in galactose, CypD is deacetylated by Sirt3 and its C/T isomerase activity declines (Shulga et al., 2010). The interaction between Sirt3 and CypD and the deacetylation of the latter is also documented in HEK cells (Hafner et al., 2010). K166 in CypD is identified as a critical site for deacetylation by Sirt3 (Table 2). This site is important for C/T isomerase activity and K166’s acetylation may increase CypD’s capacity to interact with other protein partners to induce MPT and reduce mitochondrial respiration rates (Shulga et al., 2010). Together, these studies provide an example where increased acetylation becomes detrimental, not by inhibiting enzymatic activity or protein complexes but by activating a protein to adversely affect mitochondrial functions. Nevertheless, it is increasingly recognized that not all CypD functions are detrimental to mitochondria. For example, CypD may be involved in the release of excess Ca2+ from mitochondria (Elrod et al., 2010).

**OTHER CARDIAC MODELS ASSOCIATED WITH INCREASED PROTEIN ACETYLATION**

Apart from ablation of Sirt3 (Lombard et al., 2007; Ahn et al., 2008; Fernandez-Marcos et al., 2012), a protein with documented deacetylase activity, other proteins have also been shown to have an impact on mitochondrial lysine acetylation levels, among them, Ndufs4, frataxin (frtxn), and CypD (Wagner et al., 2012; Karamanlidis et al., 2013; Nguyen et al., 2013). Ndufs4 is a subunit of complex I (NADH dehydrogenase) and its deletion in cardiac myocytes renders mitochondria deficient in complex I-driven respiration (Karamanlidis et al., 2013). Owing to complex I deficiency, the generation of NAD+ from NADH is blocked and the [NADH:NAD+] ratio is elevated. In frataxin deficiency, iron-sulfur cluster biogenesis and respiratory complex formation are impaired, again leading to elevated [NADH:NAD+] ratio (Wagner et al., 2012). In the case of CypD deficiency, mitochondria exhibit increased activity of matrix dehydrogenase complexes pyruvate dehydrogenase complex (PDHc) and KGDHc (Elrod et al., 2010) which can also elevate the [NADH:NAD+] ratio. Therefore, these gene deficiencies are characterized by increased [NADH:NAD+] ratios which would be expected to inhibit Sirt3, whose deacetylase activity is dependent on NAD+ (Figure 1) (Tanner et al., 2000). Consistently, mitochondria isolated from Ndufs4−/−, frtxn−/−, or CypD−/− hearts have altered [NADH/NAD+] ratios and hyperacetylated proteins, despite unchanged Sirt3 protein levels (Wagner et al., 2012; Karamanlidis et al., 2013; Nguyen et al., 2013). It bears noting, however, that high NADH in these models could also lead to feedback inhibition of the TCA cycle and accumulation of acetyl-CoA. In turn, this might well contribute to hyperacetylation independently of Sirt activity.

Examples of proteins whose acetylation is increased in Ndufs4−/−, frtxn−/−, and CypD−/− mitochondria are shown in Table 2. Sirt3 localizes to complex I where it deacetylates subunit Ndufa9, but fails to do so after treatment with rotenone (a complex I inhibitor) (Ahn et al., 2008). Furthermore, rotenone treatment increases mitochondrial protein acetylation to an extent similar to that observed when mitochondria are treated with nicotinamide (a sirtuin inhibitor) (Karamanlidis et al., 2013). These findings illustrate that even short term inhibition of complex I can increase protein acetylation in cardiac mitochondria. Likewise, with respect to CypD action, it would be interesting to test whether cyclosporine A (a CypD inhibitor) yields a similar result in protein acetylation. As for the downstream pathways that are affected in the three genetic models, Ndufs4−/− mitochondria have unchanged [NADPH:NADP+] ratios, unchanged aconitase activity and unchanged acetylation levels of Sod2 all consistent with normal redox defense mechanisms (Karamanlidis et al., 2013). On the other hand CypD−/− mitochondria have increased acetylation of Idh2 consistent with reduced capacity to counteract redox stress (Nguyen et al., 2013). Frtxn−/− hearts
have high levels of protein carbonylation, also suggesting reduced capacity to counteract redox stress (Wagner et al., 2012). Finally, at the level of cardiac function, Ndufs4−/− hearts have normal function at baseline which declines following pressure overload (Karamanlidis et al., 2013). Decreased heart function following pressure overload is also reported for the case of CypD, CypD, and frataxin (gene deficiencies shown in red). CypD facilitates Ca++ efflux and when absent, mitochondria exhibit higher than normal [Ca++]. This upregulates matrix dehydrogenases (e.g., TCA cycle dehydrogenases and PDH). Dehydrogenase activation enhances generation of NADH, altering the balance to higher ratios of [NADH:NAD+]+. Complex I normally converts NADH back to NAD+ but in the absence of Ndufs4 this conversion is blocked. Defects in complex I activity may also arise in the absence of Fe-S cluster biogenesis, a mitochondrial process regulated by frataxin. Although described independently (Wagner et al., 2012; Karamanlidis et al., 2013; Nguyen et al., 2013), the three conditions are similar in that they exhibit an increase in protein acetylation which may be at least in part attributable to elevation of [NADH:NAD+] ratios and lowering of Sirt3 activity. It remains to be determined whether mechanisms other than Sirt3 inhibition (e.g., elevation of acetyl-CoA) also contribute to increased acetylation in these models.

EXPANDING THE SPECTRUM OF PROTEIN LYSINE MODIFICATIONS. SUCCINYLLATION AND THE ROLE OF Sirt5

We have previously mentioned how lysine acetylation in mitochondria may be favored by the elevated pH of the matrix and the proximity of proteins to locally-generated acetyl-CoA. Yet acetyl-CoA is only one of several metabolite-CoA species generated in mitochondria (Figure 2), which given the same conditions, would also be expected to react with lysine. Again, the combination of technological advancements that led to characterization of the mitochondrial acetylome have been successfully applied for characterizing new modifications such as succinylation and malonylation.

LYSINE SUCCINYLLATION IN BACTERIA AND NON-MAMMALIAN EUKARYOTIC CELLS

Protein lysine succinylation (K-Su) results from the reaction of the dicarboxylate compound succinyl-CoA with lysine residues. The addition of a succinyl moiety to lysine adds a mass of 100 Da and imparts a negative charge at physiological pH. Using MS/MS, initial studies in E.coli identified 14 succinylated proteins including IcdA (homolog to mammalian Idh2), GapA (homolog to Gapdh) and several ribosome subunits and protein chaperones (homologs to mammalian Hsp60 and Hsp70) (Zhang et al., 2011). More recently, the tally has reached as high as 670 and 990 succinylated proteins in two recent studies (Colak et al., 2013; Weinert et al., 2013c). It is not yet clear what effects K-Su has
FIGURE 2 | Diagram showing metabolic intermediates produced in mitochondria and utilized in protein lysine modifications. The inset table highlights the structural similarities and differences among the various acyl-CoA species. Lysine acetylation, propionylation, malonylation, and succinylation have been found to dynamically change in mammalian mitochondria, while other acylation variants (e.g., butyrylation, crotonylation) await further experimental characterization.

on the function of protein substrates. To begin addressing this question, site-directed mutagenesis of K to E has been employed to mimic the creation of a K-Su site. In one experiment, a mutant IcdA K242E exhibited decreased rates of NADPH production in vitro suggesting that succinylation might be inhibitory for the dehydrogenase activity of IcdA (Zhang et al., 2011).

As in the case of acetylation, growth conditions influence the magnitude of succinylation in E.coli. Exposure to sodium succinate for 4 h increases the number of succinylated proteins (Zhang et al., 2011). Similarly, supplementation of minimal growth medium with either pyruvate, succinate or glucose, potently elevates global succinylation levels after 16 h (Colak et al., 2013). Estimates of succinylation stoichiometry on target proteins in E.coli are reported but they are only limited to a small number of proteins. The stoichiometry of protein succinylation in E.coli appears to range from 0.14 to 34%. For comparison, the stoichiometry of protein acetylation ranges from 0.22 to 73% in the same conditions (Colak et al., 2013). Succinylation (K-Su) appears to overlap considerably with acetylation (K-Ac). In E.coli grown in 0.8% glucose, K-Su and K-Ac sites overlapped by 39.3% (Colak et al., 2013), while in E.coli grown in 0.2% glucose, K-Su and K-Ac sites overlapped by 18.6% (Weinert et al., 2013c). It is not yet clear whether competition between acetyl- and succinyl-moieties for the same K site offers an additional regulatory level for controlling the activity of the protein substrate.

Bacteria contain a sirtuin-like protein (CobB) that functions as a protein deacetylase (Starai et al., 2002; Zhao et al., 2004; Weinert et al., 2013a). It was nevertheless hypothesized that CobB might have a broader specificity and function as a protein desuccinylase. Using wild-type and CobB-deficient bacteria, two studies reached different conclusions. In one study, the deletion of CobB did not induce considerable increases in global levels of protein succinylation (Weinert et al., 2013c). However, another study demonstrated that loss of CobB induced significant increases in global protein succinylation suggesting that CobB opposes protein succinylation (Colak et al., 2013). In vitro assays further confirmed CobB’s ability to desuccinylate substrate peptides and highlighted residues within the protein that might be important for interacting with the K-Su substrate (Colak et al., 2013). It should be noted that the growth conditions in the two studies were different (i.e., in the presence of 0.2 or 0.8% glucose), which might in part be responsible for the discrepancies obtained regarding the desuccinylase activity of CobB. Once the role of CobB in desuccinylation is independently corroborated, it would be interesting to determine which K-Su substrate sites are subject to regulation by this enzyme and whether the enzyme can be regulated to preferentially distinguish between K-Su and K-Ac sites.

In addition to prokaryotic cells, lysine succinylation was identified in yeast (S.cerevisiae) and SL2 cells (D.melanogaster) (Zhang et al., 2011; Xie et al., 2012; Weinert et al., 2013c), suggesting that this PTM is evolutionarily conserved. A proteome-wide study in yeast identified 474 succinylated proteins (Weinert et al., 2013c). Notwithstanding that succinyl-CoA, the primary metabolite required for succinylation, is produced inside
mitochondria (Figure 2) only a small fraction of proteins identified in the yeast succinylome (61 out of 474) map to mitochondria, while the majority are cytoplasmic and nuclear (Xie et al., 2012; Weinert et al., 2013c). Altering the availability of succinyl-CoA (by genetically ablating specific enzymes of the TCA cycle) affects the global succinylation pattern in yeast, suggesting that succinyl-CoA used for succinylation comes from mitochondria (Weinert et al., 2013c). Nevertheless, it is not yet clear how succinyl-CoA is exported to the cytoplasm. As in prokaryotic cells, K-Su and K-Ac sites tend to overlap, although in the case of yeast this is less pronounced (~16%) (Weinert et al., 2013c). While absolute stoichiometries of protein succinylation remain to be determined, the current evidence suggests that for most yeast proteins this is low, or at least much lower than the stoichiometries of phosphorylation. This evidence suggests that lysine succinylation in yeast operates as a low-grade PTM, although it might prove important for protein regulation under conditions that have yet to be identified. Another open question is whether yeast protein succinylation is subject to regulation by Sir2.

REGULATION OF PROTEIN LYSINE SUCCINYLATION BY Sirt5
Almost simultaneously, two groups made the seminal discovery that Sirt5, a mitochondrial sirtuin with only marginal deacetylase activity, had the ability to function as a desuccinylase (Du et al., 2011; Peng et al., 2011). Using a thin layer chromatography assay to monitor conversion of radiolabeled NAD$^+$ to acyl-ADP-ribose, a hallmark of sirtuin activity, it was shown that high purity SIRT5 displayed activity toward chemically synthesized succinyl-lysine peptides (Du et al., 2011). Desuccinylation by Sirt5 was confirmed by HPLC-MS or fluorescent techniques and Sirt5's activity was sensitive to inhibition by nicotinamide (Du et al., 2011; Peng et al., 2011). A crystal structure of Sirt5, in complex with a succinylated peptide, indicated that residues Y102 and R105 are important for interactions with the negatively-charged carboxyl group of the succinylated lysine (Du et al., 2011). Furthermore, R105 is suggested to confer increased sensitivity to inhibition by nicotinamide (Fischer et al., 2012). Another Sirt5 residue, H158, is important for general sirtuin catalytic activity (Schwer et al., 2002; Nakagawa et al., 2009) and, consistently, a mutant H158Y exhibits no desuccinylase activity (Du et al., 2011; Peng et al., 2011). By immobilizing Sirt5 on a column and subjecting a bovine liver mitochondrial extract to affinity purification, the first substrates of Sirt5 were identified, including Got2 (glutamate oxaloacetate transaminase 2) and Hmgcs2 (HMG-CoA synthetase 2) (Du et al., 2011). The finding that Sirt5 operates as a protein lysine desuccinylase was instrumental in characterizing the functions and regulation of this PTM, as discussed in the section below. Of note, Sirt5 exhibits broader specificity for modified lysines and in addition to desuccinylation, it can also perform demalonylation and deglutarylation (Du et al., 2011; Peng et al., 2011; Tan et al., 2014) (Figure 3).

CHARACTERIZING PROTEIN LYSINE SUCCINYLATION IN MAMMALIAN EXPERIMENTAL SYSTEMS
The study of succinylation in mammalian cells encompasses HeLa, HepG2, HEK293, and wild-type or Sirt5-deficient MEFs...
Among tissues, succinylation has been studied primarily in the liver (Du et al., 2011; Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b; Weinert et al., 2013c; Yu et al., 2013; Buler et al., 2014) and skeletal muscle (Rardin et al., 2013b; Yu et al., 2013). Sirt5−/− mice have been used in several studies (Lombard et al., 2007; Du et al., 2011; Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b; Yu et al., 2013) and in many cases mitochondria have been the focal point (Fritz et al., 2013; Park et al., 2013; Rardin et al., 2013b; Buler et al., 2014). To assess the mammalian succinylyome, three independent studies have employed polyclonal succinyl-specific antibodies to enrich for succinylated peptides that were subsequently analyzed by MS/MS approaches (Park et al., 2013; Rardin et al., 2013b; Weinert et al., 2013c).

Succinylated proteins were identified with a false-discovery rate (fdr) less than 1%. The focus of each of the studies was (i) mouse liver and HeLa cells (Weinert et al., 2013c), (ii) MLM from wild-type or Sirt5 KO mice, (Rardin et al., 2013b), and (iii) wild-type or Sirt5 KO MEFs (Park et al., 2013). In MEFs, a total of 505 succinylated proteins were identified (Park et al., 2013), whereas in HeLa cells this number reached 738, of which 272 are known mitochondrial proteins. Likewise, in whole mouse liver samples, 750 succinylated proteins were recovered, of which 310 are mitochondrial (Weinert et al., 2013c). Lastly, the analysis of purified MLM yielded 252 succinylated proteins (Rardin et al., 2013b).

Collectively, these findings show that lysine succinylation is a frequent modification in mammalian cells whose breadth and cellular localization rival that of acetylation, which prompts the question: do these PTMs target common sites? K-Su/K-Ac overlap appears to be low (~8–10%) in MEFS as well as HeLa cells (12.6%) (Park et al., 2013; Weinert et al., 2013c). By contrast, K-Su/K-Ac overlap was higher in mouse liver (24%) and reached a maximum (38.5%) in purified liver mitochondria (Rardin et al., 2013b; Weinert et al., 2013c). Given that the highest overlap is observed in mitochondria, the variations observed between cell types might reflect differences in their mitochondrial content. Moreover, the extensive overlap inside mitochondria is, again, consistent with the fact that these proteins are in proximity to the source of the acetyl- and succinyl-CoA metabolites (Wagner and Payne, 2013).

DYNAMICS AND STOICHIOMETRY OF LYSINE SUCCINYLLATION

Elucidating the rates with which proteins are succinylated/desuccinylated could lead to better predictions of how this PTM regulates downstream targets. In-depth kinetic studies specifically tailored to assess the dynamics of succinylation in different models and conditions are not yet available. Nevertheless, data from cell-free systems and in vivo show that succinylation progresses over the course of hours to days. For example, chemical (i.e., non-enzymatic) succinylation of BSA occurs within 3–6 h (Wagner and Payne, 2013; Weinert et al., 2013c). In cells, pulse-chase experiments with deuterated sodium succinate (D4) determined that succinylation gradually increases within 8–24 h (Xie et al., 2012; Park et al., 2013). In mice, global protein succinylation in liver increases at 48 h of fasting (Park et al., 2013). Moreover, mitochondrial protein succinylation in liver is reduced over the course of several weeks of ethanol exposure (Fritz et al., 2013). While these findings show that succinylation dynamics are slow, they do not rule out the possibility of faster changes under specific conditions. Future studies assessing the kinetics of succinylation/desuccinylation will need to account for the levels and activity of Sirt5 as well as the availability of succinyl-CoA.

Absolute succinylation stoichiometries were assessed in MEFS by a quantitative MS method that uses stable isotope labeling in cells (SILAC) (Park et al., 2013). The majority of quantified proteins had succinylation stoichiometries equal to or less than 10% (Park et al., 2013). Similar stoichiometry trends were obtained for succinylated sites; the site most heavily succinylated (Hspd1 K352) had a stoichiometry close to 80% but the majority of sites had stoichiometries around 15% or below (Park et al., 2013). For reference, the phosphorylation site stoichiometry in dividing HeLa cells is usually above 75% for most substrates (Olsen et al., 2010). Efforts to identify a consensus target sequence, among all succinylation sites, that might imply an enzyme-mediated PTM, have revealed no clear trends (Park et al., 2013; Rardin et al., 2013b; Weinert et al., 2013c). However, examination of sites desuccinylated by Sirt5 reveals a putative target motif in which succinyl lysine is flanked by serines and/or threonines, i.e., (S/T)-K-(S/R) (Rardin et al., 2013b).

EFFECTS OF Sirt5 ON CELL-WIDE AND MITOCHONDRIAL SUCCINYLLATION

Succinyl-CoA levels and Sirt5 activity have emerged as the main regulators of protein succinylation and desuccinylation respectively. Analysis of Sirt5 deficient tissues and cells (liver, skeletal muscle, kidney, primary hepatocytes, and MEFs) shows that loss of Sirt5 increases global succinylation, consistent with the proposed role of Sirt5 in repressing succinylation (Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b; Yu et al., 2013). Moreover, Sirt5 deficiency has no effect on global acetylation levels (Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b), nor did Sirt3 deficiency affect global succinylation (Fritz et al., 2013). To identify the in vivo substrates of Sirt5, two studies characterized the succinylome in MEFs and MLM with or without Sirt5 (Park et al., 2013; Rardin et al., 2013b). Both studies detect Sirt5 in mitochondria and the cytoplasm, implying that Sirt5 targets both compartments. Furthermore, one study identified about 120 extramitochondrial proteins whose succinylation was regulated by Sirt5 (Park et al., 2013). On the other hand, a separate study did not detect significant succinylation in the cytoplasm of liver extracts or in MEFs by western blot, although it detected prolific succinylation in purified liver mitochondria (Rardin et al., 2013b). One possible explanation for this discrepancy could be the use of different antibodies in the two studies (Park et al., 2013; Rardin et al., 2013b). Nevertheless, despite their differences, these studies provide a comprehensive picture of the Sirt5-regulated succinylome in mammalian cells, a snapshot of which is shown in Table 3 (Park et al., 2013; Rardin et al., 2013b).

REGULATION OF METABOLISM BY SUCCINYLLATION AND Sirt5

Prominent targets of succinylation are the major metabolic processes, including the TCA cycle, the pathways breaking down
Table 3 | Protein succinylation, regulation by Sirt5 and functionally important sites.

| Metabolic pathway | Substrate protein | K-Su sites targeted for desuccinylation by Sirt5 | K-Su site associated with regulation | References | Site found both as K-Su and K-Ac |
|-------------------|-------------------|-----------------------------------------------|------------------------------------|------------|---------------------------------|
| Glycolysis        | Pkm               | K498                                          | -                                  | -          | Park et al., 2013; Rardin et al., 2013a,b |
| Fatty acid oxidation | Schad            | K81                                           | -                                  | -          |                                  |
|                   | Hadha             | K60, K166, K644                              | -                                  | -          |                                  |
|                   | Eci2              | K49, K52                                      | -                                  | -          |                                  |
|                   | Lcad              | K322                                          | -                                  | -          |                                  |
|                   | Acaa2             | K209, K214                                    | -                                  | -          |                                  |
| PDHc              | Pdha              | K313, Su probably activates                  | Park et al., 2013                  | Y          |                                  |
| TCA cycle         | Cs                | K450                                          | N                                  |            |                                  |
|                   | Sdha              | K179, Su probably activates                  | Park et al., 2013                  | Y          |                                  |
|                   | Mdh2              | K239                                          | Y                                  |            |                                  |
| ETC               | Ndufb11           | K43                                           | Y                                  |            |                                  |
| OXPHOS            | Atp5a1            | K161, K427                                   | N, Y                               |            |                                  |
|                   | Atp5b             | K522, K78                                    | Y                                  |            |                                  |
|                   | Atp5h             | K78                                           | N                                  |            |                                  |
|                   | Atp5o             | K73, K90                                     | Y, Y                               |            |                                  |
|                   | Ant1              | K147                                          | N                                  |            |                                  |
|                   | Ant2              | K43, K47                                     | Y, N                               |            |                                  |
| Aminoacid catabolism | Glud1            | K90, K480                                    | Y                                  |            |                                  |
| Urea cycle        | Otc               | K221, K292                                   | Y                                  |            |                                  |
| Ketogenesis       | Cps1              | K603, K1291 Su at K1291 probably inhibits    | Du et al., 2011                    | Y, Y, Y    |                                  |
|                   | Acat1             | K260, K265                                   | Y                                  |            |                                  |
|                   | Hmgcs2            | K83, K310 K83E and K310E mutants inhibit      | Rardin et al., 2013b              | Y, Y, Y    |                                  |
|                   | Hmgcl             | K48                                           | Y                                  |            |                                  |

(Continued)
Table 3 | Continued

| Metabolic pathway          | Substrate protein | K-Su sites targeted for desuccinylation by Sirt5 | K-Su site associated with regulation | References | Site found both as K-Su and K-Ac |
|----------------------------|-------------------|-----------------------------------------------|------------------------------------|------------|----------------------------------|
|                            |                   | MEFs (Park et al., 2013) MLM (Rardin et al., 2013b) |                                    |            |                                  |
| Redox balance and sensing  | Idh2              | K413                                          | K360                               | Y          | Y                                |
|                            |                   |                                               |                                    |            |                                  |
|                            | Aco2              | K628                                          | K144                               | Y          | N                                |
|                            |                   |                                               |                                    |            |                                  |
|                            | Sod1              | Not found (n/a)                               | K123E mutant inhibits              | Lin et al., 2013 | N                              |
|                            | Sod2              | K122                                          |                                     |            |                                  |
|                            | Catalase          |                                               | K522                               | N          |                                  |
|                            | Prdx1             | K136                                          | (n/a)                              | Y          |                                  |
|                            | Me2               |                                               | K224 (n/a)                         | N          |                                  |
| Mitochondrial chaperones   | Hspa9             | K600                                          | K138                               | Y          |                                  |
|                            |                   |                                               |                                    |            |                                  |
|                            | Hspd1             | K236                                          |                                     | Y          |                                  |
|                            |                    |                                               |                                    |            |                                  |
|                            | Hspe1             |                                               | K36                                 | N          |                                  |
|                            |                   |                                               | K56                                 | Y          |                                  |
|                            | CypD              |                                               | K189                               | N          |                                  |

MEFs, mouse embryo fibroblasts; MLM, mouse liver mitochondria; n/a, not applicable (e.g., sod1 is a cytosolic/nuclear protein). All protein names can be referenced to Uniprot for more details. K-to-E are used as succinyl-mimetic mutants to probe whether the residue’s succinylation alters enzymatic activity. The table shows a short selection of sites and Sirt5 substrates. For further information the reader is referred to the indicated studies.

amino acids and fatty acids, and the protein complexes responsible for energy transfer and ATP synthesis. This tropism toward metabolic pathways should not be surprising however, since the majority of studies performed so far focus on liver, or liver-derived material (Du et al., 2011; Fritz et al., 2013; Park et al., 2013; Rardin et al., 2013b; Weinert et al., 2013c). Because succinylation is so widespread, it is challenging to precisely pinpoint the sites that are key to regulation. To this end, defining the Sirt5-regulated succinylome simplifies this quest (Table 3). However, even for this sub-fraction of the succinylome, we lack the mechanistic insights of how succinylation affects function. From a few select examples, it appears that Sirt5-mediated desuccinylation can either enhance, or repress enzymatic activity. According to one study, Sirt5 desuccinylates subunits of the pyruvate dehydrogenase complex (PDHc) and this reduces PDH’s activity (Park et al., 2013). A similar mode of regulation is suggested for respiratory complex II (SDH) (Park et al., 2013). If Sirt5 proves to have inhibitory effects on enzymes, this would distinguish it from Sirt3, which can activate enzymes by deacetylation. According to a second study however, Sirt5 has activating effects, as it desuccinylates Hmgcs2 to increase hepatic ketogenesis (Rardin et al., 2013b). Sirt5 is also suggested to desuccinylate and activate enzymes regulating fatty acid oxidation in the liver and skeletal muscle (Rardin et al., 2013b). Therefore, though it may be early to suggest that Sirt5-mediated desuccinylation generally opposes actions of Sirt3-mediated deacetylation, it does suggest that lysines targeted by both PTMs may have important regulatory roles (Table 3).

The current evidence suggests that Sirt5 down-regulates glycolysis and the TCA cycle by de-succinylating and inhibiting PDH and SDH complexes (Park et al., 2013), while in separate studies Sirt5-mediated de-succinylation up-regulates fatty acid oxidation, ketogenesis and the urea cycle by activating Hmgcs2, Cps1 and other hepatic enzymes (Du et al., 2011; Rardin et al., 2013b). In the former study, inhibition by Sirt5 was determined in MEFs and extended in HEK cells (Park et al., 2013) while, in the latter, enzyme activation was shown in mouse liver and skeletal muscle and extended to primary hepatocytes, MEFs and HEK cells (Rardin et al., 2013b). Notwithstanding the differences between experimental models and methods, Sirt5 activity might act to influence mitochondrial substrate selectivity, perhaps shunning pyruvate in favor of fatty acids.

Differences are observed regarding the birth ratios of the deficient animals; one strain yields Sirt5−/− animals at normal Mendelian ratios while a second strain yields Sirt5−/− animals at lower than normal ratios (Lombard et al., 2007; Yu et al., 2013). One strain of Sirt5−/− mice is metabolically impaired, exhibiting reduced ketogenesis and fatty acid oxidation during fasting (Rardin et al., 2013b). A second strain however, appears to be
metabolically tolerant exhibiting mild improvements in insulin sensitivity in lean and obese states (Yu et al., 2013). Nevertheless, both strains exhibit elevated blood ammonia levels (hyperammonemia) in the fasted state (Nakagawa et al., 2009; Yu et al., 2013). Although all of the above observations are not mutually exclusive, they highlight potential complexities in the regulation of metabolism by Sirt5.

PROTEIN SUCCINYLATION AND Sirt5 IN THE HEART

These are early days, indeed, for the study of succinylation in the heart. Very little data are available exploring the magnitude of protein succinylation, its implications in protein function, and its impact on cardiac function. The baseline phenotype of Sirt5−/− animals does not reveal significant cardiac abnormalities and several parameters related to heart function, including blood pressure, heart rate, and endurance exercise tolerance are normal (Yu et al., 2013). Nevertheless, mitochondria isolated from Sirt5−/− hearts exhibit considerable increases in global protein succinylation (Tan et al., 2014). At the cellular level, limited data suggest a cytoprotective role for Sirt5 in cardiac myocytes. According to one study, Sirt5 opposes H2O2–induced death in H9c2 cells and NRVMs (Liu et al., 2013). Mechanistically, the enzymatic activity of Sirt5 appears to be important for the cytoprotective effect and Sirt5 is demonstrated tophysiologically be made.

Collectively, the findings suggest potential roles of Sirt5 in stress-induced cardioprotection, but the limited number of studies and the scarcity of data on cardiac protein succinylation warrant additional investigations before firm conclusions can be made.

LYSINE MODIFICATION BY OTHER DICARBOXYLATES: MALONYLATION AND GLUTARYLATION

MALONYLATION

Malonyl-CoA is a metabolite important in fatty acid biosynthesis, derived from the carboxylation of acetyl-CoA in the cytoplasm and mitochondria (Figure 2). Lysine malonylation (K−) was identified as a new PTM that induces a mass shift of 86 kDa in the spectra of modified peptides (Du et al., 2011; Peng et al., 2011) and, similar to succinylation, malonylation of lysines adds negative charge to the modified residue (see also Figures 2, 3). Moreover, like K-Su, K-Ma is also a substrate for Sirt5 (Du et al., 2011; Peng et al., 2011). Consistently, Sirt5−/− mice exhibit enhanced protein malonylation compared to wild-type mice (Peng et al., 2011). Protein malonylation is detected in E.coli, in numerous mammalian cells and tissues; targets include mitochondrial and extramitochondrial proteins (Du et al., 2011; Peng et al., 2011; Xie et al., 2012). Using immunoenrichment followed by LC-MS/MS, 17 malonylated proteins are identified in HeLa cells (Peng et al., 2011). Another study utilizing a membrane-permeable malonate analog, labeled, and identified 375 proteins as candidates for malonylation in HeLa cells (Bao et al., 2013). Interestingly, only a small fraction of these proteins (9%) were known mitochondrial proteins (Bao et al., 2013). This may indicate that malonylation occurs predominantly on extramitochondrial locations, or perhaps that the method is less suitable for targeting of mitochondria. Isotopic labeling with sodium malonate in HeLa cells indicates that protein malonylation occurs within 24 h (mitochondrial proteins Hspa9 and Hsp1 were identified) (Peng et al., 2011). In vivo, reductions in protein malonylation (attributable to sirtuin activity) are evident within 2 h in HeLa cells (Bao et al., 2013). As mentioned previously, the dynamics of succinylation depend on the availability of succinyl-CoA (Weinert et al., 2013c). The case may be similar for malonylation as well, where exposure to sodium malonate presumably increases intracellular malonyl-CoA and potentiates protein malonylation (Peng et al., 2011). Finally, the finding that malonylation is under the negative regulation of Sirt5, cautions that current or future phenotypes identified after loss/gain-of function approaches of Sirt5 in cells and animals, can be attributable to excess protein malonylation (together with succinylation, discussed above and glutarylation, discussed below). To this point, no direct evidence is available that describes the effect of malonylation on substrate function and its role in mammalian physiology.

GLUTARYLATION

Protein glutarylation is the latest addition to the growing list of lysine acylations identified (Tan et al., 2014). Glutaryl-CoA is produced in mitochondria as a result of the catabolism of tryptophan and lysine (Borsook et al., 1948a,b; Gholson et al., 1962). Glutaryl-CoA contains a negatively charged carboxyl group and is structurally similar to malonyl-CoA and succinyl-CoA. Compared to malonylation and succinylation (identified by a shift of 86 and 100 da respectively), glutarylation causes a shift of 114 Da to the spectra of peptides bearing a modified lysine (Tan et al., 2014). Kinetic and endpoint assays using numerous substrates indicate that Sirt5 has high enzymatic activity for deglutarylation (Tan et al., 2014). The interaction of Sirt5 with malonyl-, succinyl-, and glutaryl-lysines is favored by ionic interactions between the carboxyyl group of the substrate, residues forming the substrate binding pocket of Sirt5, as well as the co-substrate, NAD+. Moreover, glutaryl-lysine is probably the largest substrate Sirt5 can accommodate, since adipoyl-lysine (which is longer than glutaryl-lysine by one methylene group) is not cleaved by Sirt5 under in vitro conditions (Tan et al., 2014).

Conditions favoring protein hyperglutarylation in cells and tissues include: (i) exposure to high concentrations of sodium glutarate, (ii) diet rich in tryptophan, (iii) deficiency of the enzyme catabolizing glutaryl-CoA (glutaryl-CoA dehydrogenase, Gcdh), (iv) prolonged fasting (i.e., for 48 h) and (v) gene deficiency of Sirt5 (Tan et al., 2014). In Sirt5−/− liver lysate, 191 glutylated proteins are identified by immunoenrichment and HPLC-MS/MS. The majority of them (148), are known mitochondrial proteins which would be consistent with mitochondria as the site of glutaryl-CoA synthesis and Sirt5 as the primary mitochondrial deglutarylase. Glutarylation accumulates on proteins over the course of several hours (within 6 h in enzyme-free reactions and up to 24 h in cells). By contrast, deglutarylation is completed as early as 30 min in the presence of Sirt5 (Tan et al., 2014).
In sum, significant parallels exist in the dynamics and regulation of glutarylation and succinylation (and to a lesser extent, malonylation) illustrating that the role of Sirt5 is more complex than once thought. Among various tissues, protein glutarylation is also detectable in heart mitochondria and it remains to be determined whether this PTM exerts important roles in cardiac function and dysfunction. A first step in addressing these issues would be to determine the baseline levels of glutaryl-CoA in the heart and test whether these fluctuate in response to physiologic and pathologic stimuli. Serving as a genetic model of glutaryl-CoA elevation, Gcdh−/− mice exhibit underlying protein hyperglutarylation (Tan et al., 2014). These mice were found to have fully functional mitochondrial respiratory complexes and normal cardiac histology (Koeller et al., 2002; Sauer et al., 2005). Reassessing the phenotype of these mice in light of protein hyperglutarylation might help identifying important regulatory functions of this PTM in cardiac function.

**STEPS TOWARD CHARACTERIZING PROPIONYLATION, BUTYRYLATION, AND CROTONYLATION**

Found in the form of thioesters with coenzyme A, propionyl-, butyryl-, and crotonyl- groups are common intermediates in energy metabolism. The breakdown of odd- and even-chain fatty acyl-CoAs through mitochondrial β-oxidation is major source of propionyl-CoA and butyryl-CoA (Figure 2). Moreover, the unsaturated variant, crotonyl-CoA derives from butyryl-CoA or glutaryl-CoA through processing by dedicated mitochondrial dehydrogenases (Green et al., 1954; Lenich and Goodman, 1986). Similarly to acetyl-CoA, propionyl-, butyryl-, and crotonyl-CoA do not have charged groups, which distinguishes them from the dicarboxylate derivatives malonyl-, succinyl-, and glutaryl-CoA which have a negatively charged group. Acetyl-CoA, propionyl-CoA, butyryl-CoA, likewise all share the same Gibbs free energy of thioester bond hydrolysis (−36 kJ/mol) (Thauer et al., 1977), and the extended family of acyl-CoA compounds may well exhibit similar reactivity toward lysine residues. Examples of lysine propionylation, butyrylation, and crotonylation (K-Pr, K-Bu, and K-Cr respectively) are identified in bacteria, yeast and mammalian cells. With a few exceptions, most studies focus on the roles these PTMs have on histone and chromatin regulation. Nevertheless, given the mitochondrial origin of propionyl-, butyryl-, and crotonyl-CoAs, it is anticipated that the repertoire of K-pr, K-bu, and K-cr will expand to include mitochondrial proteins as well. Steps toward that direction have already been made (Fritz et al., 2013; Pougovkina et al., 2014b).

**PROPIONYLATION**

K-Pr results in a shift of 56 Da on the mass of peptides bearing the modification (for comparison, K-Ac causes a shift of 42 da). In the prokaryote *S. enterica*, K-Pr is identified on the enzyme propionyl-CoA synthetase (PrpE) (Garrity et al., 2007). In mammalian cells, K-Pr is found on nuclear proteins p300, CBP, histones H3 and H4 and p53 (Chen et al., 2007; Cheng et al., 2009; Liu et al., 2009). More recently, a total of 42 propionylated proteins were identified in mouse liver, of which 23 came from the mitochondrial fraction (e.g., Acaa2, Cps1, Hmgcs2, catalase) (Fritz et al., 2013). Propionylation likely influences protein function, but specific examples are currently limited. In the case of *S. enterica*, propionylation is suggested to reduce PrpE's enzymatic activity (Garrity et al., 2007). Moreover, high levels of propionyl-CoA inhibit PDHc, αKGDHc and respiratory complex III, although lysine propionylation was not directly tested (Schwab et al., 2006).

A number of studies support that K-Pr is positively regulated by propionyltransferases. The Gcn5-related prokaryotic acetyltransferases Pat and AcaU propionylate PrpE in the presence of propionyl-CoA *in vitro* (Garrity et al., 2007). Moreover, eukaryotic acetyltransferases p300 and Cbp propionylate histones and p53 *in vitro* and *in vivo* (Chen et al., 2007; Cheng et al., 2009; Liu et al., 2009). *In vitro* evidence also shows Pcaf to operate as a propionyltransferase for histone H3 (Leemhuis et al., 2008), although Pcaf was found to be inefficient for protein propionylation in other studies (Chen et al., 2007; Cheng et al., 2009). Nuclear propionyltransferase targets include histone H3K14, H3K23, H4K12, and p53 K292. By comparison, in mitochondria, there is currently no direct evidence for an equivalent enzymatic activity. As suggested for other PTMs, propionyl-CoA levels could be a dominant force shaping the mitochondrial propionylome. Consistently, incubating liver mitochondrial lysates with increasing concentrations of propionyl-CoA elevates protein propionylation (Pougovkina et al., 2014b). Moreover, protein propionylation increases in liver mitochondria of mice exposed to ethanol for 3 or 6 weeks (Fritz et al., 2013) though whether this elevation is the result of propionyltransferase activation, depropionylase inhibition or changes in mitochondrial propionyl-CoA flux, remains to be determined. Regarding dynamics, enzymatic propionylation *in vitro* is completed within 30–120 min (Chen et al., 2007; Garrity et al., 2007; Leemhuis et al., 2008; Liu et al., 2009), whereas chemical propionylation of mitochondrial lysates progresses over the course of 3 h (Pougovkina et al., 2014b).

Negative regulation of protein propionylation by enzymes is a subject of ongoing research. The prokaryotic sirtuin homolog CobB (from the bacterium *S. enterica*) depropionylates PrpE *in vitro*, in a reaction that requires NAD⁺ and produces O-PrADPR (Garrity et al., 2007) (see Figure 3 for similar reactions). PrpE is also depropionylated by another prokaryotic sirtuin homolog (Sir2, from the bacterium *T. maritima*) and by mammalian sirtuins Sirt2 and Sirt3 (Garrity et al., 2007). Measurable *in vitro* depropionylation of synthetic peptides (H3K14-Pr, H3K23-Pr, H3K9-Pr) was also reported for sirtuins Sirt1 and Sirt2, while Sirt3 does not appear as potent (Smith and Denu, 2007; Liu et al., 2009; Feldman et al., 2013). *In vivo*, Sirt1 opposes p53’s propionylation in HEK293 cells (Cheng et al., 2009). In liver mitochondria, global protein propionylation is not significantly affected by Sirt3 deficiency (Fritz et al., 2013). Thus, the mitochondrial depropionylase remains elusive, since neither Sirt4 nor Sirt5 are efficient catalysts *in vitro* thus far (Garrity et al., 2007; Feldman et al., 2013).

Little is known regarding the stoichiometry of K-Pr. It is likely that the sites identified thus far represent those with the highest stoichiometry. For reference, K-Pr stoichiometry at H3K23 is estimated to be around 7% in a leukemia cell line (Liu et al., 2009). Moreover, K-Pr on nuclear proteins occurs rather infrequently compared to K-Ac (Cheng et al., 2009). Regarding co-occurrence
of acetylation and propionylation at the same K residue (i.e., K-Ac and K-Pr overlap), some information for nuclear proteins suggests that it exists. Moreover, considerable overlap is identified between K-Ac and K-Pr in liver mitochondria (Fritz et al., 2013). The role of lysine propionylation in human disease is only now beginning to be addressed. Deficiency in propionyl-CoA carboxylase (Pcc) in humans results in propionic aciduria, developmental and metabolic defects. Fibroblasts from these patients have protein hyperpropionylation likely resulting from propionyl-CoA accumulation (Pougovkina et al., 2014b). It remains unknown whether protein hyperpropionylation has a causative, or aggravating role in the progression of the disease. The advent of more comprehensive propionylomes will provide a better understanding of this PTM and shed light on its potential implications to cardiac disease.

**BUTYRYLATION**

Larger than propionyl-CoA by one methylene group, butyryl-CoA has similarities to propionyl-CoA in terms of its origin, ability to modify lysines and removal by putative de-butyrylases. The first examples of protein lysine butyrylation came by searching for novel PTMs in histone proteomics data. Following a series of validation steps, mass shifts of 70 da in modified peptides were assigned to lysine butyrylation (K-Bu) in histones H3, H4, and nuclear proteins p53, p300, and CBP (Chen et al., 2007; Cheng et al., 2009). In the case of histone H4, butyrylated lysines (e.g., H4K5, H4K8, H4K12, H4K31) were also found to be propionylated, attesting to a significant overlap between K-Bu and K-Pr (Chen et al., 2007). Among 5 HATs, only CBP and p300 can operate as butyryl-transferases in vitro and this activity is extended in vivo (Chen et al., 2007; Cheng et al., 2009). Owing to CBP and p300 activity, p53 is butyrylated at two positions, K373 and K382 in lung cancer cells (Cheng et al., 2009). Histone butyrylation is also detected in the mouse brain (e.g., H2AK95 and H3K115) (Tweedie-Cullen et al., 2012). There, the stoichiometry of K-Bu at H3K115 was found to be 31%, implying a critical role of butyrylation at this histone site.

In mitochondria, K-Bu is readily detectable by a butyryl-lysine-specific antibody (Fritz et al., 2013). This antibody can be useful in enriching for butyrylated peptides from mitochondrial proteins and identifying them with mass spectrometry, Sirt3 deficiency does not dramatically alter butyrylation in MLM suggesting that Sirt3 is not a major regulator (Fritz et al., 2013), in apparent agreement with in vitro studies showing that Sirt3 has low de-butyrylation activity (Smith and Denu, 2007; Feldman et al., 2013). While it is unclear what sirtuin opposes mitochondrial butyrylation (Sirt4 and Sirt5 have no debutyrylase activity; Feldman et al., 2013), emerging evidence suggests that butyryl-CoA flux is a major determinant of butyrylation rates. Genetic deficiency in butyryl-CoA dehydrogenase substantially increases protein butyrylation in liver and this is attributed to aberrant accumulation of hepatic butyryl-CoA (Pougovkina et al., 2014b). Since butyrylation is upregulated, this genetic model could be useful in deciphering the regulatory enzymes opposing protein hyperbutyrylation and also help identify important substrates undergoing butyrylation in various tissues including liver and heart.

**CROTONYLATION**

The identification crotonylation as a novel lysine PTM (68 Da), stems directly from efforts to increase histone protein coverage by derivitizing peptides with propionic anhydride prior to HPLC-MS/MS (Tan et al., 2011). Comparison of the HPLC-MS/MS spectra and elution properties of synthetic and in vivo peptides, validated K-Cr as a naturally occurring PTM. This was further substantiated by identifying K-Cr sites after isotopic labeling with D4-crotonate in cells, and with detection of modified proteins using anti-crotonyl-lysine specific antibody (Tan et al., 2011). Examples of K-Cr sites on histones include H2AK36, H2BK5, H3K23, and H4K12. A separate study identifies K-Cr on brain histones, including H2AK95, H2BK108, H3K122, and H4K91, with stoichiometries ranging from 1–36% (Tweedie-Cullen et al., 2012). In contrast to other lysine acylations, K-Cr is structurally more rigid, as the double bond restricts rotation of the carbon atoms. Whether this rigidity has unique implications in histone function remains unknown. One interesting observation is that histone crotonylation is very frequent in gene enhancers and it prevents chromosome inactivation of differentiating sperm cells (Tan et al., 2011).

While the above study laid the framework, questions still remain about the regulation of K-Cr and its impact on non-histone and perhaps mitochondrial proteins. The dynamics of K-Cr are likely governed by crotonyl-CoA levels. Altering the flux of crotonyl-CoA (a metabolic intermediate in fatty acid and amino acid catabolism) could directly affect global mitochondrial protein crotonylation. Studies are also designed to identify enzymatic activities promoting or opposing crotonylation. In contrast to what has been shown for propionylation and butyrylation, the HATs p300 and CBP do not promote crotonylation (Tan et al., 2011). Furthermore, none of the 11 histone deacetylases (HDACs) can decrotonylate efficiently (Tan et al., 2011). A screen of the sirtuins for decrotonylation activity using a synthetic peptide (H4K12-Cr) found Sirt1 to be somewhat active, while Sirt2, 3, 5 and 6 had negligible activity (Madsen and Olsen, 2012). A separate study using a different substrate (H3K9-Cr) found measurable decrotonylation activities in Sirt1 and Sirt2 but not in Sirt3-Sirt6 (Feldman et al., 2013). In aggregate, sirtuins Sirt3-Sirt5 are unlikely to be decrotonylases, so a dedicated mitochondrial decrotonylase remains to be discovered. An alternative possibility is that the crotonyl moiety is modified in situ to become the substrate of one of the mitochondrial sirtuins (e.g., conversion of K-Cr to K-Ac through a series of enzymatic steps and final deacetylation by Sirt3).

The importance of K-Cr to mitochondrial protein activity has yet to be established. A genetic model of protein hypercrotonylation would be valuable in this regard, just as Gcdh and Bcdh-null models have provided insights into the roles hyperglutarylation and hyperbutyrylation respectively (Pougovkina et al., 2014b; Tan et al., 2014). Protein hypercrotonylation might be possible by inactivating crotonase, a multisubunit enzyme converting crotonyl-CoA to 3-hydroxybutyryl-CoA (Engel et al., 1996). One limitation could be that the levels of enoyl-CoA intermediates other than crotonyl-CoA might be affected, since crotonase has broad specificity (Waterson and Hill, 1972; Schulz, 1974; Fong and Schulz, 1977). More investigation is warranted for this newly
discovered PTM and its potential implications in mitochondrial protein regulation in heart and other tissues.

CONCLUSIONS

Once exclusively the purview of histone research, the study of lysine PTMs has undergone a profound maturation. Mitochondria are epicenters for an evolving class of lysine PTMs including succinylation, malonylation, and glutarylation. The result has been a data deluge. And so begins the daunting task of piecing it all together and sorting the regulatory PTMs from the ephiphenomena of metabolic stress (Beltrao et al., 2012). And with these discoveries comes the realization that newer tools may be required to assess the causal relationship between PTM and protein function. For instance, until now, mutation of K to Q/E has served as an accepted mimic of the charge neutralization of acetylation, while K to E mutation has served to mimic the negative charge of succinylation. Are these mutations equally suitable for the study of propionylation, malonylation, and glutarylation, whose size differ? Promisingly, Neumann et al. have developed a method to introduce site-specific acetylated lysine residues in recombinant proteins expressed in E.coli (Neumann et al., 2008). If the method can be honed to incorporate other modified lysines, it will be possible to test their effect on function and the extent to which K to Q/E mutation may serve as a valid proxy in mammalian cell culture.

The new lysine modifications join the pantheon of metabolic PTMs, including O-GlcNacylation and palmitoylation among others. And while great strides have been made to understand how specific nutrients act as ligands to activate transcriptional programs to modulate metabolism, it is also clear now that metabolism, itself, leaves its mark on the proteome in a manner that ultimately affects the activity of enzymes. This increased complexity and nuanced regulation may afford new opportunities for therapeutic intervention in disease and the mitochondrial sirtuins promise to be prime targets. Already, emerging evidence shows that increasing the availability of NAD$^+$ for sirtuins with NAD analogues and 32P-NAD.

SOURCES OF FUNDING

D. Brian Foster is supported by NIH R21HL108052, an American Heart Association National Scientist Development Grant, 12SDG12060056, and funding from the Zegar Family Foundation. Brian O’Rourke acknowledges funding from HHSN268201000032C.

REFERENCES

Ahn, B. H., Kim, H. S., Song, S., Lee, J. H., Liu, J., Vassilopoulos, A., et al. (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105, 14447–14452. doi: 10.1073/pnas.0803790105

Ahuja, N., Schwer, B., Carobbio, S., Waltzegnry, D., North, B. J., Castronovo, V., et al. (2007). Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J. Biol. Chem. 282, 33583–33592. doi: 10.1074/jbc.M700548200

Allfrey, V., Faulkner, R., and Mirsky, A. E. (1964). Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 51, 786–788. doi: 10.1073/pnas.51.5.786

Baeza, J., Dowell, J. A., Smellgen, M. L., Fan, J., Amador-Noguez, D., Khan, Z., et al. (2014). Stoichiometry of site-specific lysine acetylation in an entire proteome. J. Biol. Chem. 289, 21326–21338. doi: 10.1074/jbc.M114.581843

Bao, J., Lu, Z., Joseph, J. I., Carabenciov, D., Dimond, C. C., Pang, L., et al. (2010). Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylation activity of long and short SIRT3 isoforms. J. Cell. Biochem. 110, 238–247. doi: 10.1002/jcb.22531

Bao, X., Zhao, Q., Yang, T., Fung, Y. M., and Li, X. D. (2013). A chemical probe for lysine malonylation. Angewandte Chemie 52, 4883–4886. doi: 10.1002/anie.201300252

Beltrao, P., Albanese, V., Kenner, L. R., Swaney, D. L., Burlingame, A., Villen, J., et al. (2012). Systematic functional prioritization of protein posttranslational modifications. Cell 150, 413–425. doi: 10.1016/j.cell.2012.05.036

Bharathi, S. S., Zhang, Y., Mohsen, A. W., Uppala, R., Balasubramani, M., Schreiber, E., et al. (2013). Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. J. Biol. Chem. 288, 33857–33847. doi: 10.1074/jbc.M113.510554

Borsook, H., Deasy, C. L., Haagen-Smit, A. J., Keighley, G., and Lowy, P. H. (1948a). The degradation of l-lysine in guinea pig liver homogenate; formation of alpha-aminoacidic acid. J. Biol. Chem. 176, 1383–1393.

Borsook, H., Deasy, C. L., Haagen-Smit, A. J., Keighley, G., and Lowy, P. H. (1948b). The degradation of alpha-aminoacidic acid in guinea pig liver homogenate. J. Biol. Chem. 176, 1395–1400.

Butler, M., Atsinski, S. M., Izz1, V., Uswimia, J., and Hakkola, J. (2014). SIRT5 is under the control of PGC-1alpha and AMPK and is involved in regulation of mitochondrial energy metabolism. FASEB J. 28, 3223–3237. doi: 10.1096/fj.13-245241

Canto, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., et al. (2012). The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847. doi: 10.1016/j.cmet.2012.04.022

Chen, C. J., Fu, Y. C., Yu, W., and Wang, W. (2013). SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-kappaB. Biochem. Biophys. Res. Commun. 430, 798–803. doi: 10.1016/j.bbrc.2012.11.066

Chen, Y., Sprung, R., Tang, Y., Ball, H., Sangras, B., Kim, S. C., et al. (2007). Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics 6, 812–819. doi: 10.1074/mcp.M700211-MCP200

Chen, Y., Zhang, J., Lin, Y., Lei, Q., Guan, K. L., Zhao, S., et al. (2011). Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 12, 534–541. doi: 10.1038/embor.2011.65

Cheng, Z., Tang, Y., Chen, Y., Kim, S., Liu, H., Li, S. S., et al. (2009). Molecular characterization of propionyllysines in non-histone proteins. Mol. Cell. Proteomics 8, 45–52. doi: 10.1074/mcp.M800224-MCP200

Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehmam, M., Walthier, T. C., et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 253, 843–846. doi: 10.1126/science.1157371

Colah, G., Xie, Z., Zhu, A. Y., Dai, L., Lu, Z., Zhang, Y., et al. (2013). Identification of lysine succinylation substrates and the succinylation regulatory enzyme CobB in Escherichia coli. Mol. Cell. Proteomics 12, 3509–3520. doi: 10.1074/mcp.M113.031567

Csabi, A., Fendt, S. M., Li, C., Poulgiannis, G., Choo, A. Y., Chapski, D. J., et al. (2013). The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153, 840–854. doi: 10.1016/j.cell.2013.04.023

Du, J., Jiang, H., and Lin, H. (2009). Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD. Biochemistry 48, 2878–2890. doi: 10.1021/bi802093g

Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., et al. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 808–809. doi: 10.1126/science.1207861

Elrod, J. W., Wong, R., Mishra, S., Vagnozzi, R. J., Sakhitevel, B., Goonasekera, S. A., et al. (2010). Cyclophilin D controls mitochondrial pore-dependent Cal(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J. Clin. Invest. 120, 3680–3687. doi: 10.1172/JCI43171
Lysine modifications in mitochondria

Still, A. J., Floyd, B. J., Hebert, A. S., Bingman, C. A., Carson, J. J., Gunderson, D. R., Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L., et al. (2014). Lysine acetylation is a highly abundant and evolutionarily conserved modification in Escherichia coli. J. Biol. Chem. 289, 1529–1536.

Yu, J., Sadhukhan, S., Noriega, L. G., Moullan, N., He, B., Weiss, R. S., et al. (2013). Metabolic characterization of a Sir2deficient mouse model. Science 338, 2806–2810.

Yu, W., Dittenhafer-Reed, K. E., and Denu, J. M. (2012). SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J. Biol. Chem. 287, 14078–14086. doi: 10.1074/jbc.M112.355206

Yu, W., Lin, Y., Yao, J., Huang, W., Lei, Q., Xiong, Y., et al. (2009). Lysine acetylation negatively regulates ornithine carbamoyltransferase activity in response to nutrient signals. J. Biol. Chem. 284, 13669–13675. doi: 10.1074/jbc.M901212000

Zhang, J., Sprung, R., Pei, J., Tan, X., Kim, S., Zhu, H., et al. (2009). Lysine acetylation is a highly abundant and evolutionarily conserved modification in Escherichia coli. Mol. Cell. Proteomics 8, 215–225. doi: 10.1074/mcp.M800187-MCP200

Zhang, K., Zheng, S., Yang, J. S., Chen, Y., and Cheng, Z. (2013). Comprehensive profiling of protein lysine acetylation in Escherichia coli. J. Proteome Res. 12, 844–851. doi: 10.1021/pr300912q

Zhang, Z., Tan, M., Xie, Z., Dai, L., Chen, Y., and Zhao, Y. (2011). Identification of lysine succinylation as a new post-translational modification. Nat. Chem. Biol. 7, 58–63. doi: 10.1038/nchembio.495

Zhao, K., Chai, X., and Marmorstein, R. (2004). Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Escherichia coli. J. Mol. Biol. 337, 731–741. doi: 10.1016/j.jmb.2004.01.060

Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., et al. (2010). Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004. doi: 10.1126/science.1179689

Zhu, W. Z., Wu, X. F., Zhang, Y., and Zhou, Z. N. (2012). Proteomic analysis of mitochondrial proteins in cardiomyocytes from rats subjected to intermittent hypoxia. Eur. J. Appl. Physiol. 112, 1037–1046. doi: 10.1007/s00421-010-1950-9

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 May 2014; accepted: 23 July 2014; published online: 02 September 2014. Citation: Papanicolaou KN, O’Rourke B and Foster DB (2014) Metabolism leaves its mark on the powerhouse: recent progress in post-translational modifications of lysine in mitochondria. Front. Physiol. 5:301. doi: 10.3389/fphys.2014.00301

This article was submitted to Mitochondrial Research, a section of the journal Frontiers in Physiology. Copyright © 2014 Papanicolaou, O’Rourke and Foster. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.